Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Iron infusion Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Endothelial Hyperpolarization in Humans

NCT00166166
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Tetraethylammonium (TEA), L-NG-monomethyl Arginine (L-NMMA), Bradykinin, Sodium nitroprusside, Acetylcholine, Saline, Fluconazole
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Colorado-Oregon Altitude Study

NCT05734716
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride
Drug
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Leadville, Colorado • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 29, 2026, 4:07 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

NCT02189889
View directory record Official record
Conditions
Anemia, Cardiovascular Disease
Interventions
EPO, Feraheme
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia

NCT05047211
View directory record Official record
Conditions
Anemia, Iron Deficiency, Delivery Complication
Interventions
Ferrous sulfate, Iron dextran
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 29, 2026, 4:07 AM EDT
Terminated Not applicable Interventional Results available

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

NCT00578292
View directory record Official record
Conditions
Thalassemia
Interventions
Busulfan, Fludarabine, Campath 1H, Cyclophosphamide, MESNA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers

NCT02767128
View directory record Official record
Conditions
Iron-refractory, Iron-deficiency Anemia (IRIDA)
Interventions
Triferic, Fer-In-Sol, Shohl's solution
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03237065
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions
Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Muscle Shoals, Alabama • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

NCT02962648
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Deficiency Anaemia
Interventions
Iron isomaltoside/ferric derisomaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Chula Vista, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 29, 2026, 4:07 AM EDT
Terminated Phase 1Phase 2 Interventional

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

NCT03933813
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions
Iron Sucrose
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

NCT01280240
View directory record Official record
Conditions
Patients With Chemotherapy Induced Anemia (CIA)
Interventions
Monofer(R)
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Baltimore, MD, Maryland • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Early Phase 1 Interventional

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

NCT02452216
View directory record Official record
Conditions
Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation, Hemorrhagic Cerebrovascular Accident, Ischemic Cerebrovascular Accident, Primary Brain Neoplasm, Brain Cancer, Brain Tumors
Interventions
Ferumoxytol, Tissue Analysis, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Michael Iv
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 29, 2026, 4:07 AM EDT
Recruiting Early Phase 1 Interventional

Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction

NCT07634640
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Ferumoxytol infusion
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 3 Interventional

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

NCT00093912
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, sodium nitroprusside
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Montgomery, Alabama • Burbank, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Sep 29, 2026, 4:07 AM EDT
Terminated Phase 1 Interventional

Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

NCT02222363
View directory record Official record
Conditions
Refractory Cancer
Interventions
VLX600
Drug
Lead sponsor
Vivolux AB
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

NCT02940860
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions
Iron isomaltoside/ferric derisomaltose, Iron sucrose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
141
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

NCT03738943
View directory record Official record
Conditions
Receptor Blockade
Interventions
Adenosine Triphosphate, Acetylcholine, Sodium Nitroprusside, Adenosine Diphosphate, Adenosine Monophosphate, Uridine Triphosphate, Adenosine, Vitamin B 6, Pyridoxal 5'-Phosphate
Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 29, 2026, 4:07 AM EDT
Withdrawn Phase 4 Interventional

Predicting Stroke Risk in ICAD With Novel MRI

NCT05515874
View directory record Official record
Conditions
Intracranial Atherosclerosis
Interventions
Feraheme
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02940886
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions
Iron isomaltoside/ferric derisomaltose, Iron sucrose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
1,512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
114
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 4 Interventional Results available

Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)

NCT00920023
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Superparamagnetic Iron Oxide Magnetic Resonance Imaging
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia

NCT01374919
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
ferumoxytol
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 29, 2026, 4:07 AM EDT
Terminated Phase 4 Interventional

Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure

NCT05816265
View directory record Official record
Conditions
Heart Failure, Iron-deficiency
Interventions
IV Iron Infusion Group
Drug
Lead sponsor
Radha Gopalan
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 29, 2026, 4:07 AM EDT
Completed Early Phase 1 Interventional

Novel Imaging Markers in SPMS

NCT05357833
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
Interventions
Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine
Drug · Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 29, 2026, 4:07 AM EDT
Recruiting Phase 3 Interventional

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

NCT04268849
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 29, 2026, 4:07 AM EDT